{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:18:37Z","timestamp":1773328717012,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.resinv.2025.10.015","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:30:44Z","timestamp":1762309844000},"page":"1330-1337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exacerbation and cardiopulmonary risk after prompt initiation of single-inhaler budesonide \/glycopyrrolate\/formoterol fumarate following COPD exacerbations: Insights from MITOS EROS (Japan) study"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0461-5072","authenticated-orcid":false,"given":"Koichiro","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Makita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3640-4034","authenticated-orcid":false,"given":"Zhao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6698-6093","authenticated-orcid":false,"given":"Aaro","family":"Salosensaari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6906-1392","authenticated-orcid":false,"given":"Catarina","family":"Camarinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9286-752X","authenticated-orcid":false,"given":"Reiko","family":"Yamaura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Cuntin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7351-3059","authenticated-orcid":false,"given":"Michael","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.resinv.2025.10.015_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.46598","article-title":"Global burden of chronic obstructive pulmonary disease through 2050","volume":"6","author":"Boers","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.resinv.2025.10.015_bib3","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1111\/ggi.13091","article-title":"Prevalence of chronic obstructive pulmonary disease in independent community-dwelling older adults: the Fujiwara-kyo study","volume":"17","author":"Yoshikawa","year":"2017","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.resinv.2025.10.015_bib4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/COPD.S346591","article-title":"Frequency and severity of exacerbations of COPD associated with future risk of exacerbations and mortality: a UK routine health care data study","volume":"17","author":"Whittaker","year":"2022","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"4","key":"10.1016\/j.resinv.2025.10.015_bib5","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.amjmed.2024.11.007","article-title":"Effectiveness of single versus multiple inhaler triple therapy on mortality and cardiopulmonary risk reduction in COPD: the SKOPOS-MAZI study","volume":"138","author":"Pollack","year":"2024","journal-title":"Am J Med"},{"key":"10.1016\/j.resinv.2025.10.015_bib6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/COPD.S438893","article-title":"Risk of death and cardiovascular events following an exacerbation of COPD: the EXACOS-CV US study","volume":"19","author":"Daniels","year":"2024","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"1","key":"10.1016\/j.resinv.2025.10.015_bib7","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12931-023-02601-4","article-title":"Risk of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: results from the EXACOS-CV cohort study using the PHARMO data network in the Netherlands","volume":"24","author":"Swart","year":"2023","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.resinv.2025.10.015_bib8","article-title":"Elucidating the risk of cardiopulmonary consequences of an exacerbation of COPD: results of the EXACOS-CV study in Germany","volume":"11","author":"Claus","year":"2024","journal-title":"BMJ Open Respirat Res"},{"issue":"12","key":"10.1016\/j.resinv.2025.10.015_bib9","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/resp.13620","article-title":"Increased risk of major adverse cardiac events following the onset of acute exacerbations of COPD","volume":"24","author":"Reilev","year":"2019","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2025.10.015_bib10","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2147\/COPD.S407085","article-title":"All-cause, cardiovascular and respiratory mortality in people with type 2 diabetes and chronic obstructive pulmonary disease (COPD) in England: a cohort study using the clinical practice research datalink (CPRD)","volume":"18","author":"Raslan","year":"2023","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.resinv.2025.10.015_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/17534666211070139","article-title":"The long-term clinical impact of COPD exacerbations: a 3-year observational study (SHERLOCK)","volume":"16","author":"Haughney","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.resinv.2025.10.015_bib12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2147\/COPD.S389297","article-title":"History of respiratory events prior to a first COPD diagnosis and future exacerbations: a longitudinal observational cohort database study in Japan","volume":"18","author":"Ding","year":"2023","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"8","key":"10.1016\/j.resinv.2025.10.015_bib13","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1007\/s12325-024-02920-y","article-title":"Increased risk of severe cardiovascular events following exacerbations of chronic obstructive pulmonary disease: results of the EXACOS-CV study in Japan","volume":"41","author":"Matsunaga","year":"2024","journal-title":"Adv Ther"},{"issue":"6","key":"10.1016\/j.resinv.2025.10.015_bib14","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.resinv.2023.08.007","article-title":"Management goals and stable phase management of patients with chronic obstructive pulmonary disease in the Japanese respiratory society guideline for the management of chronic obstructive pulmonary disease 2022 (6th edition)","volume":"61","author":"Shibata","year":"2023","journal-title":"Respirat Invest"},{"key":"10.1016\/j.resinv.2025.10.015_bib15","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2147\/COPD.S450270","article-title":"Underdiagnosis of COPD: the Japan COPD real-world data epidemiological (CORE) study","volume":"19","author":"Koga","year":"2024","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"4","key":"10.1016\/j.resinv.2025.10.015_bib17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/eurheartj\/ehad669","article-title":"Exacerbating the burden of cardiovascular disease: how can we address cardiopulmonary risk in individuals with chronic obstructive pulmonary disease?","volume":"45","author":"Shrikrishna","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.resinv.2025.10.015_bib18","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.2147\/COPD.S329316","article-title":"Overcoming therapeutic inertia to reduce the risk of COPD exacerbations: four action points for healthcare professionals","volume":"16","author":"Singh","year":"2021","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.resinv.2025.10.015_bib19","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.2147\/COPD.S211854","article-title":"Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease","volume":"14","author":"Sicras Mainar","year":"2019","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"9","key":"10.1016\/j.resinv.2025.10.015_bib20","first-page":"e338","article-title":"Outcomes associated with timing of maintenance treatment for COPD exacerbation","volume":"18","author":"Dalal","year":"2012","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.resinv.2025.10.015_bib21","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2147\/COPD.S102570","article-title":"Prompt initiation of maintenance treatment following a COPD exacerbation: outcomes in a large insured population","volume":"11","author":"D'Souza Coutinho","year":"2016","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.resinv.2025.10.015_bib22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40248-018-0151-6","article-title":"The effect of delaying initiation with umeclidinium\/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models","volume":"13","author":"Buikema","year":"2018","journal-title":"Multidiscip Respir Med"},{"issue":"12","key":"10.1016\/j.resinv.2025.10.015_bib23","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.18553\/jmcp.2022.28.12.1366","article-title":"Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: an analysis of the PRIMUS study","volume":"28","author":"Evans","year":"2022","journal-title":"J Manag Care Special Pharma"},{"issue":"12","key":"10.1016\/j.resinv.2025.10.015_bib24","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1007\/s12325-024-02999-3","article-title":"Fluticasone furoate\/umeclidinium\/vilanterol initiation following a COPD exacerbation: benefits of prompt initiation on COPD outcomes","volume":"41","author":"Mannino","year":"2024","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.resinv.2025.10.015_bib25","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12931-022-02184-6","article-title":"Effect of timing of bronchodilator therapy initiation on exacerbations in patients with chronic obstructive pulmonary disease: a retrospective cohort study","volume":"23","author":"Yamada","year":"2022","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2025.10.015_bib26","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.2147\/COPD.S419119","article-title":"Benefit of prompt Vs delayed initiation of triple therapy following an exacerbation in patients with COPD in Japan: a retrospective cohort study","volume":"18","author":"Czira","year":"2023","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"6","key":"10.1016\/j.resinv.2025.10.015_bib27","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.21037\/jtd-20-2263","article-title":"Narrative review of current COPD status in Japan","volume":"13","author":"Tanabe","year":"2021","journal-title":"J Thorac Dis"},{"issue":"6","key":"10.1016\/j.resinv.2025.10.015_bib28","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/MLR.0b013e31819432e5","article-title":"A modification of the elixhauser comorbidity measures into a point system for hospital death using administrative data","volume":"47","author":"van Walraven","year":"2009","journal-title":"Med Care"},{"key":"10.1016\/j.resinv.2025.10.015_bib29","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.2147\/COPD.S432963","article-title":"Exacerbations and real-world outcomes after single-inhaler triple therapy of budesonide\/glycopyrrolate\/formoterol fumarate, among patients with COPD: results from the EROS (US) study","volume":"18","author":"Strange","year":"2023","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"10356","key":"10.1016\/j.resinv.2025.10.015_bib31","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0140-6736(22)01273-9","article-title":"Towards the elimination of chronic obstructive pulmonary disease: a lancet commission","volume":"400","author":"Stolz","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2025.10.015_bib32","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.2147\/COPD.S165187","article-title":"Understanding low COPD exacerbation rates in Japan: a review and comparison with other countries","volume":"13","author":"Ishii","year":"2018","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"12","key":"10.1016\/j.resinv.2025.10.015_bib33","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1007\/s12325-024-02994-8","article-title":"Characteristics of patients with COPD initiating budesonide\/glycopyrronium\/formoterol or other triple therapies in Japan: a real-world healthcare claims database study (MITOS-AURA)","volume":"41","author":"Takahashi","year":"2024","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.resinv.2025.10.015_bib34","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1440-1843.2004.00637.x","article-title":"COPD in Japan: the nippon COPD epidemiology study","volume":"9","author":"Fukuchi","year":"2004","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.resinv.2025.10.015_bib35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12931-022-01949-3","article-title":"Effect of indacaterol\/glycopyrronium on ventilation and perfusion in COPD: a randomized trial","volume":"23","author":"Singh","year":"2022","journal-title":"Respir Res"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525001741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525001741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:52:30Z","timestamp":1773280350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534525001741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2212534525001741"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2025.10.015","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exacerbation and cardiopulmonary risk after prompt initiation of single-inhaler budesonide \/glycopyrrolate\/formoterol fumarate following COPD exacerbations: Insights from MITOS EROS (Japan) study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2025.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of The Japanese Respiratory Society.","name":"copyright","label":"Copyright"}]}}